
The benefit of cabozantinib with or without immune checkpoint inhibition (ICI) in previously heavily treated patients with advanced sarcoma is not clear. Retrospective study of heavily pretreated advanced sarcoma patients who received cabozantinib with or without ICI. There were 105 eligible patients with thirty-one different histologic subtypes, a median age of 56 years, and 55% were female. The median lines of prior treatment were four. Approximately 40.9% of patients were treated with cabozantinib alone and 59.1% were treated with cabozantinib plus either nivolumab, nivolumab plus ipilimumab, or pembrolizumab. The progression-free survival (PFS) of the full cohort was 3.3 months. Eight patients (7.6%) obtained a partial response (PR), and forty-two patients (40.0%) had stable disease (SD) longer than 3 months, with a clinical benefit rate (CBR) of 47.6%. The median PFS and overall survival (OS) for the 47.6% of patients who obtained a clinical benefit (PR + SD) were 6.9 and 22.9 months, compared to the median PFS of 2.1 months (p < 0.001) and median OS of 7.4 months (p = 0.001) for the patients with progressive disease. Several patients with aggressive histologic subtypes, including osteosarcoma, desmoplastic small round cell tumor, synovial sarcoma, and others, had a PFS of more than 12 months. There was no significant difference in PFS or OS between patients treated with cabozantinib only and patients treated with cabozantinib plus ICI. In a cohort of heavily pretreated patients with advanced soft tissue and bone sarcoma, cabozantinib alone or with ICI showed durable CBR in nearly 50% of patients, suggesting cabozantinib alone or with ICI could be a viable treatment option.
Human papillomavirus type 16 (HPV16)-positive head and neck cancer (HNC) is generally associated with a more favourable prognosis than HPV-negative disease. However, emerging evidence suggests that specific HPV16 genomic variants may be associated with poorer clinical outcomes. We therefore conducted a systematic review of HPV16 single nucleotide polymorphisms (SNPs) reported in HNC and mapped selected variants to viral genomic and protein regions to assess their potential relevance. We searched four major databases (PubMed, Embase, Scopus, and Web of Science) for studies reporting HPV16 SNPs in HNC. Most studies focused on either E6 or E7, while only a few studies examined the entire HPV16 sequence. These SNPs were extracted and mapped to the HPV16 genome, while structural and functional characteristics were assessed using UniProt and the RCSB Protein Data Bank. Fourteen studies were analysed, identifying 30 SNPs in E6 and seven in E7. Structural mapping suggested that core HPV16 oncogenic motifs remain highly conserved, while recurrent variants tend to occur in mutationally permissive regions, such as the E6 interdomain linker. Only one study reported associations between HPV16 variants and poorer patient survival within the upstream regulatory region. However, these findings require independent validation before any clinical relevance can be established. The comprehensive mapping of HPV16 SNPs in HNC provides an important grounding for understanding how these SNPs may be associated with disease progression and patient outcomes. Although many of the identified SNPs are within important HPV16 regions, their associations with disease progression remain unclear. Further studies are required to determine which variants are associated with patient outcomes. A more comprehensive understanding of HPV16 genomic variation and its relevance could provide broader clinical insights across HPV16-associated cancers.
Cancer of Unknown Primary (CUP) is a heterogeneous group of cancers for which a primary site cannot be identified. The diagnostic pathway is often protracted and resource-intensive, with little known about the costs involved. The primary aims of this study were to (a) determine time-to-treatment-decision (pathway duration) and (b) estimate resources incurred and direct healthcare costs within the UK’s diagnostic pathway. A microcosting analysis was conducted on 370 patients with CUP. For relevant context, a comparison cohort of 216 patients with stage IV cholangiocarcinoma (CCA) was selected. Pathways were mapped from the first cancer-related investigation until treatment decision. Analyses estimated pathway duration and cost, and explored the significance of prognostic variables on the CUP pathway. Median pathway duration in CUP was 40% longer than CCA (2.8 months vs 2.0 months, respectively, p < 0.001). Mean per-patient cost of the CUP pathway was 62% higher than CCA (£3902 vs £2403 respectively, p < 0.001). Performance status 0-1 and squamous-cell histology were predictive of higher costs in CUP. Direct healthcare costs were significantly higher in CUP. Improvements are required to rationalise investigations and facilitate patients receiving treatment in an appropriate timeframe.
Abstract Introduction Current spatial proteomic approaches quantify immune checkpoint expression but do not directly measure functional receptor-ligand (PD-1/PD-L1) interactions within the tumour-immune microenvironment (TiME). Therapeutic antibodies disrupt receptor-ligand interactions and do not target protein abundance; therefore, methods capable of resolving functional checkpoint interactions may provide biologically distinct insight beyond expression-based assays. Methods We developed FuncO:TiME by integrating functional oncology mapping (FuncOmap), histopathology and multiplex spatial immune profiling to map PD-1/PD-L1 interaction states within clinically annotated melanoma tissues collected before and after neoadjuvant immune checkpoint blockade (ICB). Results FuncOmap quantified millions of per-pixel PD-1/PD-L1 interactions and revealed marked spatial heterogeneity in checkpoint interactions that were not reflected by PD-1 or PD-L1 expression alone. Post-treatment tissues exhibited increased PD-1/PD-L1 interaction states despite no corresponding increase in expression, highlighting the divergence between functional checkpoint interactions and expression-based measurements. Integrating with spatial immune profiling further demonstrated the feasibility of contextualising regional differences in interaction states within distinct immune populations and patterns of PD-1/PD-L1 expression in melanoma TiMEs. Conclusion We establish the feasibility of FuncO:TiME spatially resolved mapping of functional checkpoint interactions in human melanoma tissues. Our findings demonstrate that receptor-ligand interactions diverge from checkpoint protein expression patterns and support further development of integrated approaches that contextualise functional checkpoint interactions within cellular features of the TiME. Such approaches may enable deeper investigation of checkpoint biology and inform the future development of functionally informed biomarkers for cancer immunotherapy.
MiR-662 overexpression has been reported to promote breast cancer metastatic progression and to impair the expression of genes encoding for proteins involved in translation, ribosome biogenesis and ribosome processing (Puppo et al., 2023); however, the relationship between miR-662 and the translational machinery was not further investigated at the time. MiR-662 was overexpressed in MDA-MB-231-luc2 (NW1) human breast cancer cells. Global protein synthesis was analyzed using polysome profiles. Potential defects in rRNA 47S precursor biogenesis were evaluated by Northern blot. C/D box snoRNA (SNORD) expression was quantified by a medium-throughput RT-qPCR microfluidic dynamic array. rRNA 2’O-ribose methylation (2’Ome) was profiled using RiboMethSeq. No changes in rRNA synthesis, processing, or maturation were observed upon miR-662 overexpression. In contrast, a marked reduction in the ratio of polysomal to free ribosomal fractions was observed, indicating an impaired mRNA engagement into translation. Interestingly, a drastic decrease in SNORD levels (but not of their host genes) and a global decrease in rRNA 2’Ome was observed upon miR-662 overexpression. The involvement of miRNAs in snoRNA-induced modulation in rRNA epitranscriptomic marks might be a novel mechanism of fine regulation of the ribosome composition with possible repercussions on breast cancer metastatic progression.